Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazole for Primary Treatment of Chinese Patients With Invasive Fungal Disease
NCT05630976Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of isavuconazole in invasive fungal disease (IFD), sponsored by Pfizer. Started Feb 2023; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive fungal disease (IFD)
Beyond the preview
Go deeper on NCT05630976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630976.